Observational studyAlimentary pharmacology & therapeutics2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.
Observational study in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.Alimentary pharmacology & therapeutics · 2026Article
- Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.Alimentary pharmacology & therapeutics · 2026Observational
- Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study.Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsRisankizumab, a selective interleukin-23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate-to-severe Crohn's disease, but real-world data in highly refractory populations are limited. We evaluated the short-term effectiveness and outcomes at last follow-up of risankizumab and the impact of prior advanced therapy exposure.
methodsThis multicentre observational study included adult patients with predominantly refractory Crohn's disease treated with risankizumab and registered in the ENEIDA registry. Steroid-free clinical remission, defined as a Harvey-Bradshaw Index ≤ 4 without systemic corticosteroids, was assessed at weeks 8-12 and at the last available follow-up visit. Multivariable logistic regression was used to identify factors associated with remission at last follow-up.
resultsA total of 857 patients with predominantly refractory Crohn's disease were included. Steroid-free clinical remission was achieved in 56% of patients at weeks 8-12 and in 61% at last follow-up (mean follow-up: 7.4 months). Remission rates were higher in patients previously exposed to ≤ 2 biologic therapies than in those exposed to > 2 biologic therapies at both time points (p < 0.001). Prior ustekinumab exposure was associated with lower remission rates in unadjusted analyses but was not independently associated with remission at last follow-up. Treatment-related adverse events occurred in 8% of patients, with no serious adverse events.
conclusionsIn this large real-world cohort of patients with refractory Crohn's disease, risankizumab achieved clinically meaningful steroid-free clinical remission, both at early assessment and at last follow-up, with effectiveness primarily influenced by cumulative biologic exposure and demonstrating a favourable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.